Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia
NCT ID: NCT01972178
Last Updated: 2015-10-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
113 participants
INTERVENTIONAL
2013-11-30
2014-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To evaluate the efficacy of PRC-4016 by assessment of the percentage change in blood lipids and lipoprotein parameter from baseline after 12 weeks of treatment
* To evaluate the safety of PRC-4016 as assessed by adverse events and other safety parameters
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PRC-4016
PRC-4016, oral administration once daily, capsule
PRC-4016
Statins
Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
Placebo
Placebo, oral administration once daily, capsule
Placebo
Statins
Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PRC-4016
Placebo
Statins
Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-HDL-C \> 130 mg/dl
* Stable statin treatment
Exclusion Criteria
* Recent cardiovascular or coronary event
* History of pancreatitis
* History or evidence of major and clinically significant diseases that would interfere with the conduct of the study or interpretation of data
* Uncontrolled hypertension
18 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pronova BioPharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pål Nord, MD, MPH
Role: STUDY_DIRECTOR
Pronova BioPharma
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medical Affiliated Research Center, Inc.
Huntsville, Alabama, United States
Terence Hart, MD
Muscle Shoals, Alabama, United States
Pacific Oaks Medical Group
Beverly Hills, California, United States
National Research Institute - Wilshire
Los Angeles, California, United States
Research Across America - Santa Ana
Santa Ana, California, United States
Encompass Clinical Research
Spring Valley, California, United States
Jacksonville Impotence Treatment Center
Jacksonville, Florida, United States
Compass Research East, LLC
Oviedo, Florida, United States
Progressive Medical Research
Port Orange, Florida, United States
Meridien Research
St. Petersburg, Florida, United States
Meridien Research- Tampa
Tampa, Florida, United States
Evanston Premier Healthcare Research LLC
Evanston, Illinois, United States
Medisphere Medical Research Center
Evansville, Indiana, United States
Heartland Research Assoc., LLC
Newton, Kansas, United States
Louisville Metabolic and Atherosclerosis Research Center (L-MARC)
Louisville, Kentucky, United States
Troy Internal Medicine, P.C.
Troy, Michigan, United States
Radiant Research - Edina
Edina, Minnesota, United States
Peters Medical Research
High Point, North Carolina, United States
PMG Research of Raleigh, LLC
Raleigh, North Carolina, United States
Sterling Research Group, Ltd. - Auburn
Cincinnati, Ohio, United States
Metabolic and Atherosclerosis Research Center
Cincinnati, Ohio, United States
Columbus Clinical Research, Inc.
Columbus, Ohio, United States
PSB Research/P. S. Bains, M.S., D.O.
Marion, Ohio, United States
RAS Health Ltd
Marion, Ohio, United States
Willamette Valley Clinical Studies
Eugene, Oregon, United States
Green and Seidner Family Practice Associates
Lansdale, Pennsylvania, United States
Padre Coast Clinical Research
Corpus Christi, Texas, United States
National Clinical Research - Norfolk, Inc.
Norfolk, Virginia, United States
National Clinical Research - Richmond, Inc.
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTN 4016 13202
Identifier Type: -
Identifier Source: org_study_id